INGN vs RMD
INGN: Inogen is a medical technology company developing portable oxygen concentrators and respiratory devices to improve mobility and quality of life for patients with chronic lung diseases like COPD. RMD: ResMed develops cloud-connected software platforms and digital devices for out-of-hospital care, spanning sleep apnea management, COPD treatment, and residential care operations.
Side-by-side fundamentals
| Metric | INGN | RMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.51 | $192.91 | |
| Market cap as of 2026-07-23 | $174M | $28.2B | |
| P/E as of 2026-07-23 | n/a | 18.56 | |
| PEG as of 2026-07-23 | n/a | 1.15 | |
| Net margin as of 2026-07-23 | -7.1% | +27.4% | RMD higher |
| Gross margin as of 2026-07-23 | +44.3% | +61.6% | RMD higher |
| Operating margin as of 2026-07-23 | -9.1% | +34.2% | RMD higher |
| ROE as of 2026-07-23 | -12.9% | +24.4% | RMD higher |
| ROA as of 2026-07-23 | -8.3% | +18.0% | RMD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.10 | INGN lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.4% | +10.3% | RMD higher |
| Revenue CAGR (3y) SEC XBRL | -2.6% | +12.9% | RMD higher |
| Dividend yield as of 2026-07-23 | n/a | +1.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.61 | 0.76 | |
| 1-year return as of 2026-07-22 close | +2.7% | -27.9% | INGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.